Education
About Us
Working with TipRanks
Follow Us
Jasper Therapeutics (JSPR)
NASDAQ:JSPR
Total Valuation
Jasper Therapeutics has a market cap or net worth of $62.49M. The enterprise value is $251.06M.
Market Cap$62.49M
Enterprise Value$251.06M
Share Statistics
Jasper Therapeutics has 15.02M shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding15.02M
Owned by Insiders27.62%
Owned by Instutions0.02%
Financial Efficiency
Jasper Therapeutics’s return on equity (ROE) is ― and return on invested capital (ROIC) is ―.
Return on Equity (ROE)―
Return on Assets (ROA)―
Return on Invested Capital (ROIC)―
Return on Capital Employed (ROCE)―
Revenue Per Employee$18,343.75
Profits Per Employee$0
Employee Count64
Asset Turnover―
Inventory Turnover―
Valuation Ratios
The current PE Ratio of Jasper Therapeutics is ―. Jasper Therapeutics’s PEG ratio is ―.
PE Ratio―
PS Ratio―
PB Ratio―
Price to Fair Value―
Price to FCF―
Price to Operating Cash Flow―
PEG Ratio―
Income Statement
In the last 12 months, Jasper Therapeutics had revenue of $1.17M and earned $0.00 in profits. Earnings per share was -$0.02.
Revenue$1.17M
Gross Profit$0.00
Operating Income-$76.24M
Pretax Income$0.00
Net Income$0.00
EBITDA-3.95M
Earnings Per Share (EPS)-0.02
Cash Flow
In the last 12 months, operating cash flow was -$62.60M and capital expenditures -$552.00K, giving a free cash flow of -$63.15M billion.
Operating Cash Flow-$62.60M
Free Cash Flow-$63.15M
Free Cash Flow per Share-$4.20
Dividends & Yields
Jasper Therapeutics pays an annual dividend of , resulting in a dividend yield of
Dividend Per Share
Dividend Yield
Payout Ratio
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta2.25
52-Week Price Change-82.62%
50-Day Moving Average5.25
200-Day Moving Average15.45
Relative Strength Index (RSI)40.90
Average Volume (3m)240.08K
Important Dates
Jasper Therapeutics upcoming earnings date is May 9, 2025, After Close.
Last Earnings DateFeb 27, 2025
Next Earnings DateMay 9, 2025
Ex-Dividend Date―
Financial Position
Jasper Therapeutics as a current ratio of ―, with Debt / Equity ratio of ―
Current Ratio―
Quick Ratio―
Debt to Market Cap―
Net Debt to EBITDA―
Interest Coverage Ratio―
Taxes
In the past 12 months, Jasper Therapeutics has paid $0.00 in taxes.
Income Tax$0.00
Effective Tax Rate―
Enterprise Valuation
Jasper Therapeutics EV to EBITDA ratio is ―, with an EV/FCF ratio of ―.
EV to Sales―
EV to EBITDA―
EV to Free Cash Flow―
EV to Operating Cash Flow―
Balance Sheet
Jasper Therapeutics has $71.64M in cash and marketable securities with $1.81M in debt, giving a net cash position of -$69.82M billion.
Cash & Marketable Securities$71.64M
Total Debt$1.81M
Net Cash-$69.82M
Net Cash Per Share-$4.65
Tangible Book Value Per Share―
Margins
Gross margin is ―, with operating margin of ―, and net profit margin of ―.
Gross Margin―
Operating Margin―
Pretax Margin―
Net Profit Margin―
EBITDA Margin―
EBIT Margin―
Analyst Forecast
The average price target for Jasper Therapeutics is $60.38, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$60.38
Price Target Upside1337.62%
Analyst ConsensusStrong Buy
Analyst Count11
Revenue Growth Forecast
EPS Growth Forecast21.40%